This article is a text version of a Wall Street Journal newsletter published earlier today.

Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic ...

She regularly appears on CBS News 24/7 to discuss her reporting. Regeneron has agreed to buy 23andMe, the once buzzy genetic testing company, out of bankruptcy for $256 million under a court ...

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based drugmaker is set to take over 23andMe after winning a ...

Developer of the blockbuster drug Eyelea, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has a strong and diverse pipeline that enabled it to post more than $14 billion in sales last year. Regeneron ...

Regeneron Pharmaceuticals (REGN) reported its first-quarter 2025 earnings, revealing a miss on both earnings and revenue expectations. The company posted earnings per share (EPS) of $8.22, falling ...

Analysts at Leerink agreed with Sanofi that ... This matches or exceeds the performance of Sanofi and Regeneron’s prized drug Dupixent and Amgen and AstraZenca’s Tezspire—two products that are ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a ...

In a note sent to investors Tuesday, Leerink Partners analyst Daina Graybosch ... as 2seventy already divested its R&D assets to Regeneron and Novo Nordisk, and [Bristol Myers Squibb] manufactures ...

A live webcast link for the Leerink Partners Global Biopharma Conference ... while the worst include UnitedHealth Group and Regeneron Pharmaceuticals. We sell different types of products and ...